CRYO CELL INTERNATIONAL INC·4

Sep 18, 4:53 PM ET

PORTNOY DAVID 4

4 · CRYO CELL INTERNATIONAL INC · Filed Sep 18, 2025

Insider Transaction Report

Form 4
Period: 2025-09-16
PORTNOY DAVID
DirectorChairman, Co-CEO10% Owner
Transactions
  • Purchase

    Common Stock

    2025-09-16$4.46/sh+6,449$28,763818,369 total
  • Purchase

    Common Stock

    2025-09-18$4.46/sh+3,411$15,213827,344 total
  • Purchase

    Common Stock

    2025-09-17$4.43/sh+5,564$24,649823,933 total
  • Purchase

    Common Stock

    2025-09-18$4.49/sh+1,751$7,862161,833 total(indirect: By Corporation)
Holdings
  • Common Stock

    (indirect: By IRA)
    268,878
  • Common Stock

    (indirect: As Custodian for son)
    11,398
  • Stock Option

    Exercise: $7.53From: 2019-08-30Exp: 2029-08-30Common stock (26,243 underlying)
    26,243
  • Stock Option

    Exercise: $6.47From: 2023-12-22Exp: 2028-12-22Common Stock (50,000 underlying)
    50,000
  • Common Stock

    (indirect: By Corporation)
    57,306
  • Stock Option

    Exercise: $4.77From: 2023-01-03Exp: 2028-01-03Common Stock (50,000 underlying)
    50,000
  • Common Stock

    (indirect: As Custodian for son)
    11,537
  • Common Stock

    (indirect: As Custodian for son)
    10,939
  • Stock Option

    Exercise: $4.30From: 2022-12-23Exp: 2027-12-23Common Stock (50,000 underlying)
    50,000
  • Common Stock

    (indirect: By 401(k))
    164,182
  • Common Stock

    (indirect: By Spouse)
    107,403
  • Stock Option

    Exercise: $7.28From: 2019-12-20Exp: 2029-12-20Common Stock (23,636 underlying)
    23,636
  • Common Stock

    (indirect: By LLC)
    59,027
  • Stock Option

    Exercise: $12.27From: 2021-12-22Exp: 2028-12-22Common Stock (280,000 underlying)
    280,000
  • Stock Option

    Exercise: $8.08From: 2025-01-21Exp: 2030-01-21Common Stock (50,000 underlying)
    50,000
Footnotes (10)
  • [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.40 to $4.47, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F10]Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.
  • [F2]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.41 to $4.45, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F3]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.45 to $4.50, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F4]Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary.
  • [F5]Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary.
  • [F6]Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership.
  • [F7]Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term.
  • [F8]8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026.
  • [F9]Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4